February 24, 2016
1 min read

Extended-release tofacitinib approved by FDA for RA treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Pfizer announced an extended-release formulation of tofacitinib has been approved by the FDA for the treatment of moderate-to-severe rheumatoid arthritis, according to a company press release.

The product is a once-daily, 11-mg oral Janus kinase (JAK) inhibitor, indicated for patients with an inadequate response or with intolerance to methotrexate. The extended-release formulation of tofacitinib (Xeljanz XR, Pfizer) can be taken with or without concomitant methotrexate or other disease-modifying antirheumatic drugs.

Roy Fleischmann

“The availability of Xeljanz XR provides physicians with a new treatment option for people with RA who may prefer an oral once-daily treatment,” Roy Fleischmann, MD, clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and co-medical director of the Metroplex Clinical Research Center, said in a press release.

The FDA approved a 5-mg dose of tofacitinib in November 2012. According to the release, Xeljanz XR 11 mg administered once daily is pharmacokinetically equivalent to Xeljanz 5 mg administered twice daily.

As noted in the press release, tofacitinib has been studied in trials with over 6,200 patients amounting to more than 19,400 patient-years of drug exposure.

Reference: http://www.pfizer.com